Compare · ELV vs VRDN
ELV vs VRDN
Side-by-side comparison of Elevance Health Inc. (ELV) and Viridian Therapeutics Inc. (VRDN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and VRDN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $92.91B, about 41.9x VRDN ($2.22B).
- ELV has hit the wire 3 times in the past 4 weeks while VRDN has been quiet.
- VRDN has more recent analyst coverage (25 ratings vs 23 for ELV).
- Company
- Elevance Health Inc.
- Viridian Therapeutics Inc.
- Price
- -
- -
- Market cap
- $92.91B
- $2.22B
- 1M return
- -
- -13.05%
- 1Y return
- -
- -21.31%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 3
- 0
- Recent ratings
- 23
- 25
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Viridian Therapeutics Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Latest ELV
- SEC Form 4 filed by Elevance Health Inc.
- Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026
- Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- EVP & Chief Legal Officer Wessling Erin M covered exercise/tax liability with 349 shares, decreasing direct ownership by 5% to 7,230 units (SEC Form 4)
- EVP & Chief HR Officer Craig Ryan R covered exercise/tax liability with 144 shares, decreasing direct ownership by 2% to 6,530 units (SEC Form 4)
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
Latest VRDN
- Chief Legal Officer Tousignant Jennifer sold $348,194 worth of shares (14,212 units at $24.50) and exercised 10,000 shares at a strike of $14.41, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Tripuraneni Radhika exercised 40,000 shares at a strike of $13.21 (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Viridian Therapeutics Inc.
- SEC Form 10-Q filed by Viridian Therapeutics Inc.
- Viridian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
- SEC Form 4 filed by Director Morris Arlene
- SEC Form 4 filed by Director Kiselak Tomas
- SEC Form 4 filed by Director Gheuens Sarah
- SEC Form 4 filed by Director Moses Jennifer K.